In vivo selection of anti-HIV-1 gene-modified human hematopoietic stem/progenitor cells to enhance engraftment and HIV-1 inhibition

By sjmartinez • February 10, 2024

Guo Q, Zhang J, Parikh K, Brinkley A, Lin S, Zakarian C, Pernet O, Shimizu S, Khamaikawin W, Hacke K, Kasahara N, An DS. In vivo selection of anti-HIV-1 gene-modified human hematopoietic stem/progenitor cells to enhance engraftment and HIV-1 inhibition. Mol Ther. 2024 Feb 7;32(2):384-394. doi: 10.1016/j.ymthe.2023.12.007. Epub 2023 Dec 12. PMID: 38087779.

Tags: 6-thioguanine, C46 HIV-1 fusion inhibitor, CCR5, Hematology/Oncology, hematopoietic stem/progenitor cell based gene therapy, HIV-1, HSPC, humanized mouse, hypoxanthine-guanine phosphoribosyl transferase, in vivo selection, Publications, short hairpin RNA

Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasm

De Botton S, Récher C, Cortes J, Curti A, Fenaux P, Peterlin P, Pigneux A, Yee K, Wei A, Mims A, Schiller G, Chao MM,[...]

Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now

Shore N, Nielsen SM, Esplin ED, Antonarakis ES, Barata PC, Beer TM, Beltran H, Bryce A, Cookson MS, Crawford ED, Dorff TB, George DJ, Heath[...]

Retrospective Study of CD20 Expression Loss in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Marshalek JP, Qing X, Dragan M, Tomassetti S. Retrospective Study of CD20 Expression Loss in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. J Hematol. 2024 Dec;13(6):268-277.[...]